Connection

MITCHELL FREDERICK to Cell Proliferation

This is a "connection" page, showing publications MITCHELL FREDERICK has written about Cell Proliferation.
Connection Strength

0.316
  1. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. 2017 04 28; 392:71-82.
    View in: PubMed
    Score: 0.076
  2. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul; 9(7):1968-76.
    View in: PubMed
    Score: 0.048
  3. Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma. Cancer Res. 2022 12 02; 82(23):4444-4456.
    View in: PubMed
    Score: 0.028
  4. PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. Clin Cancer Res. 2019 06 01; 25(11):3329-3340.
    View in: PubMed
    Score: 0.022
  5. CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res. 2018 02 01; 78(3):781-797.
    View in: PubMed
    Score: 0.020
  6. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. Clin Cancer Res. 2017 Nov 01; 23(21):6541-6554.
    View in: PubMed
    Score: 0.020
  7. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins. Clin Cancer Res. 2015 Nov 01; 21(21):4831-44.
    View in: PubMed
    Score: 0.017
  8. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther. 2015 Feb; 14(2):608-19.
    View in: PubMed
    Score: 0.016
  9. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck. 2014 Nov; 36(11):1547-54.
    View in: PubMed
    Score: 0.016
  10. Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2014 Mar; 36(3):375-84.
    View in: PubMed
    Score: 0.015
  11. Establishment and characterization of novel cell lines from sinonasal undifferentiated carcinoma. Clin Cancer Res. 2012 Nov 15; 18(22):6178-87.
    View in: PubMed
    Score: 0.014
  12. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011 Apr 15; 17(8):2281-91.
    View in: PubMed
    Score: 0.012
  13. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer. 2011 Jul 01; 117(13):2926-38.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.